JP2011500007A - βアミロイドおよび／またはアミロイド状物質のヒトおよび／または動物の臓器および組織への異常堆積を特徴とするヒトおよび／または動物の病理の診断、予防、および／または、処置のための製品およびその利用法、および、病理の危険性を判定するスクリーニング方法 - Google Patents
βアミロイドおよび／またはアミロイド状物質のヒトおよび／または動物の臓器および組織への異常堆積を特徴とするヒトおよび／または動物の病理の診断、予防、および／または、処置のための製品およびその利用法、および、病理の危険性を判定するスクリーニング方法 Download PDFInfo
- Publication number
- JP2011500007A JP2011500007A JP2010528323A JP2010528323A JP2011500007A JP 2011500007 A JP2011500007 A JP 2011500007A JP 2010528323 A JP2010528323 A JP 2010528323A JP 2010528323 A JP2010528323 A JP 2010528323A JP 2011500007 A JP2011500007 A JP 2011500007A
- Authority
- JP
- Japan
- Prior art keywords
- human
- mutation
- amyloid
- app
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 title claims abstract description 30
- 230000007170 pathology Effects 0.000 title claims abstract description 28
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title claims abstract description 26
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title claims abstract description 26
- 238000011282 treatment Methods 0.000 title claims abstract description 21
- 230000002159 abnormal effect Effects 0.000 title claims abstract description 20
- 230000008021 deposition Effects 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 20
- 241001465754 Metazoa Species 0.000 title claims abstract description 19
- 238000003745 diagnosis Methods 0.000 title claims abstract description 14
- 230000002265 prevention Effects 0.000 title claims abstract description 14
- 238000012216 screening Methods 0.000 title claims abstract description 12
- 210000001557 animal structure Anatomy 0.000 title claims 10
- 230000035772 mutation Effects 0.000 claims abstract description 88
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 56
- 102220006209 rs193922916 Human genes 0.000 claims abstract description 43
- 210000000056 organ Anatomy 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 230000008506 pathogenesis Effects 0.000 claims abstract description 5
- 239000012634 fragment Substances 0.000 claims description 45
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 claims description 37
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 claims description 31
- 102000046783 human APP Human genes 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 22
- 108020004705 Codon Proteins 0.000 claims description 21
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims description 18
- 108010029485 Protein Isoforms Proteins 0.000 claims description 17
- 102000001708 Protein Isoforms Human genes 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 14
- 230000009261 transgenic effect Effects 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 10
- 230000001575 pathological effect Effects 0.000 claims description 8
- 230000002068 genetic effect Effects 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- 108010036933 Presenilin-1 Proteins 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 6
- 230000006870 function Effects 0.000 claims description 6
- 102000013498 tau Proteins Human genes 0.000 claims description 6
- 108010026424 tau Proteins Proteins 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- 230000009368 gene silencing by RNA Effects 0.000 claims description 5
- 238000001415 gene therapy Methods 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 101100268553 Homo sapiens APP gene Proteins 0.000 claims description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 3
- 208000031295 Animal disease Diseases 0.000 claims description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 2
- 229940104302 cytosine Drugs 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229940104230 thymidine Drugs 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 102000012419 Presenilin-2 Human genes 0.000 claims 3
- 108010036908 Presenilin-2 Proteins 0.000 claims 3
- 238000002659 cell therapy Methods 0.000 claims 3
- 210000001082 somatic cell Anatomy 0.000 claims 3
- 102000012412 Presenilin-1 Human genes 0.000 claims 2
- 239000012620 biological material Substances 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000252212 Danio rerio Species 0.000 claims 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 125000003636 chemical group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000013011 mating Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 23
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 239000002243 precursor Substances 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 description 23
- 230000008901 benefit Effects 0.000 description 19
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 10
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000011830 transgenic mouse model Methods 0.000 description 8
- 102100022033 Presenilin-1 Human genes 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 6
- 101150031224 app gene Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 5
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 210000004897 n-terminal region Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010050254 Presenilins Proteins 0.000 description 4
- 102000015499 Presenilins Human genes 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 4
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000017488 activation-induced cell death of T cell Effects 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 208000015756 familial Alzheimer disease Diseases 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002981 neuropathic effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 102000001049 Amyloid Human genes 0.000 description 2
- 108010094108 Amyloid Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
- 101800001415 Bri23 peptide Proteins 0.000 description 2
- 101800000655 C-terminal peptide Proteins 0.000 description 2
- 102400000107 C-terminal peptide Human genes 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 description 2
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 2
- 230000003942 amyloidogenic effect Effects 0.000 description 2
- 230000007450 amyloidogenic pathway Effects 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 230000006652 catabolic pathway Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- OIMKESDGUJKJQX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) [4-(dodecylcarbamoyl)-9H-fluoren-9-yl]methyl carbonate Chemical compound CCCCCCCCCCCCNC(=O)c1cccc2C(COC(=O)ON3C(=O)CCC3=O)c3ccccc3-c12 OIMKESDGUJKJQX-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- 101000823042 Mus musculus Amyloid-beta precursor protein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006518 acidic stress Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 208000021024 autosomal recessive inheritance Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220009395 rs63750847 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000010246 ultrastructural analysis Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 125000005289 uranyl group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001975A ITMI20071975A1 (it) | 2007-10-12 | 2007-10-12 | Prodotti e loro uso per la diagnosi prevenzione e-o cura di patologie umane e-o animali caraterizzate dalla anomala deposizione di sostanza b-amiloide e-o similamiloide in organi e tesstui umani e-o animali e metodo di screening per la determinazione |
| PCT/EP2008/008595 WO2009047002A2 (en) | 2007-10-12 | 2008-10-10 | Products and their use for the diagnosis, prevention, and/or care of human and/or animal pathologies characterised by the anomalous deposition of b-amyloid and/or amyloid-like substance in human and/or animal organs and tissues, and screening method for determining the risk of such pathologies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011500007A true JP2011500007A (ja) | 2011-01-06 |
| JP2011500007A5 JP2011500007A5 (enExample) | 2011-05-12 |
Family
ID=40313814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528323A Pending JP2011500007A (ja) | 2007-10-12 | 2008-10-10 | βアミロイドおよび／またはアミロイド状物質のヒトおよび／または動物の臓器および組織への異常堆積を特徴とするヒトおよび／または動物の病理の診断、予防、および／または、処置のための製品およびその利用法、および、病理の危険性を判定するスクリーニング方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110010785A1 (enExample) |
| EP (1) | EP2220251B1 (enExample) |
| JP (1) | JP2011500007A (enExample) |
| CN (1) | CN102037136A (enExample) |
| ES (1) | ES2607897T3 (enExample) |
| IT (1) | ITMI20071975A1 (enExample) |
| WO (1) | WO2009047002A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024500768A (ja) * | 2020-12-18 | 2024-01-10 | ベイラー カレッジ オブ メディスン | 凝集抑制のためのＡβ変異体の伝達 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010001198A1 (de) * | 2010-01-26 | 2011-07-28 | Robert Bosch GmbH, 70469 | Verfahren zur Identifikation von Verbrauchern bzw. Erzeugern in einem pneumatischen, hydraulischen oder elektrischen Netz |
| US9238796B2 (en) | 2010-06-04 | 2016-01-19 | Toagosei Co. Ltd. | Cell growth-promoting peptide and use thereof |
| JP5650249B2 (ja) * | 2011-01-07 | 2015-01-07 | セイコーエプソン株式会社 | アミロイド前駆体タンパク質のシグナルペプチドに対する抗体 |
| WO2013180011A1 (ja) | 2012-05-28 | 2013-12-05 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| WO2014061749A1 (ja) | 2012-10-18 | 2014-04-24 | 東亞合成株式会社 | ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用 |
| CN102943126A (zh) * | 2012-12-12 | 2013-02-27 | 芮屈生物技术（上海）有限公司 | 老年性痴呆病变前期APP基因mRNA水平原位杂交筛查试剂盒及筛查方法和应用 |
| DE102013201324B4 (de) | 2013-01-28 | 2024-05-16 | Aktiebolaget Skf | Verfahren zum Bestimmen einer Lagervorspannung |
| CN106574930B (zh) * | 2014-05-22 | 2019-09-03 | 株式会社岛津制作所 | 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法 |
| US20160011616A1 (en) * | 2014-07-11 | 2016-01-14 | Microsoft Technology Licensing, Llc | Power management |
| WO2016172955A1 (zh) * | 2015-04-30 | 2016-11-03 | 江苏挪贝肽医药科技有限公司 | 一种筛选用于治疗阿尔茨海默病的药物和治疗靶点的方法 |
| CN109776665B (zh) * | 2019-02-02 | 2021-02-05 | 首都医科大学宣武医院 | 阿尔茨海默病新突变、其稳转细胞模型及医药用途 |
| IT201900010722A1 (it) * | 2019-07-02 | 2021-01-02 | Fondazione Irccs St Neurologico Carlo Besta | Composto e composizione per il trattamento multi-obiettivo di disturbi legati alla proteina tau |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7196163B2 (en) * | 2001-05-22 | 2007-03-27 | Merk & Co., Inc. | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity |
| US20050106731A1 (en) * | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| BRPI0610093A2 (pt) * | 2005-05-05 | 2008-12-09 | Merck & Co Inc | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente |
| MX2008006957A (es) * | 2005-11-30 | 2008-10-20 | Abbott Lab | Metodos para la preparacion de formas recombinantes de proteina beta-amiloide humana y usos de estas proteinas. |
-
2007
- 2007-10-12 IT IT001975A patent/ITMI20071975A1/it unknown
-
2008
- 2008-10-10 CN CN2008801213173A patent/CN102037136A/zh active Pending
- 2008-10-10 WO PCT/EP2008/008595 patent/WO2009047002A2/en not_active Ceased
- 2008-10-10 EP EP08838209.8A patent/EP2220251B1/en active Active
- 2008-10-10 US US12/682,578 patent/US20110010785A1/en not_active Abandoned
- 2008-10-10 ES ES08838209.8T patent/ES2607897T3/es active Active
- 2008-10-10 JP JP2010528323A patent/JP2011500007A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024500768A (ja) * | 2020-12-18 | 2024-01-10 | ベイラー カレッジ オブ メディスン | 凝集抑制のためのＡβ変異体の伝達 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102037136A (zh) | 2011-04-27 |
| ITMI20071975A1 (it) | 2009-04-13 |
| ES2607897T3 (es) | 2017-04-04 |
| US20110010785A1 (en) | 2011-01-13 |
| EP2220251A2 (en) | 2010-08-25 |
| EP2220251B1 (en) | 2016-08-03 |
| WO2009047002A3 (en) | 2009-08-06 |
| WO2009047002A2 (en) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500007A (ja) | βアミロイドおよび／またはアミロイド状物質のヒトおよび／または動物の臓器および組織への異常堆積を特徴とするヒトおよび／または動物の病理の診断、予防、および／または、処置のための製品およびその利用法、および、病理の危険性を判定するスクリーニング方法 | |
| Hadano et al. | Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking | |
| Kim et al. | MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival | |
| Hou et al. | Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease | |
| Chang et al. | In-frame deletion in a novel centrosomal/ciliary protein CEP290/NPHP6 perturbs its interaction with RPGR and results in early-onset retinal degeneration in the rd16 mouse | |
| US20050214837A1 (en) | Antibody specific for mutant presenilin 1 and method of use thereof | |
| JP2000506375A (ja) | アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用 | |
| Traka et al. | WDR81 is necessary for purkinje and photoreceptor cell survival | |
| JP2011500007A5 (enExample) | ||
| Graw et al. | Characterization of a new, dominant V124E mutation in the mouse αA-crystallin–encoding gene | |
| JP2004517634A (ja) | 神経変性疾患の同定と治療のための方法及び組成物 | |
| US11122784B2 (en) | Parkinson's disease model and methods | |
| WO2000078934A2 (en) | Use of the ubiquitin specific protease usp25 in the diagnosis and treatment of alzheimer's disease | |
| US6664443B1 (en) | Pathogenic Tau mutations in transgenic mice | |
| Botta et al. | Expression analysis and protein localization of the human HPC-1/syntaxin 1A, a gene deleted in Williams syndrome | |
| JP2000516087A (ja) | アルツハイマー病に関連する遺伝子配列およびタンパク質、ならびにその使用 | |
| JP2006517383A (ja) | ｔｏｒｓｉｎ遺伝子をコードするヌクレオチド配列、ｔｏｒｓｉｎタンパク質、これらを用いてタンパク質凝集を治療する方法 | |
| KR101336786B1 (ko) | Ｖｐｓ２６ｂ 유전자 결손에 의한 퇴행성 신경계 뇌질환 모델 마우스 및 이의 제조 방법 | |
| US6207878B1 (en) | Sarcospan-deficient mouse as a model for clinical disorders associated with sarcospan mutations | |
| JP2004522408A (ja) | プレセニリンエンハンサー | |
| Bekris et al. | Genetics of Neurodegenerative Diseases | |
| Ikeda et al. | Towards understanding the function of the tubby gene family in the retina | |
| Hewitt | Investigating the functions of LARGE: lessons from mutant mice | |
| JP2024170682A (ja) | プロテアソーム機能減弱トランスジェニック非ヒト動物 | |
| Prihar | Genetic and functional analysis of the presenilins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110318 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110318 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120710 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120710 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130514 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131015 |